Table S3 from A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma
crossref(2023)
摘要
Table S3 shows grade {greater than or equal to}3 adverse events (regardless of relationship to study drug) in {greater than or equal to}2 patients in total phase 1 population
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要